Bimagrumab
Bimagrumab
Bimagrumab (pronounced as bi-ma-gru-mab) is a monoclonal antibody designed for the treatment of sarcopenia and muscle wasting conditions. It is developed by Novartis, a Swiss multinational pharmaceutical company.
Etymology
The name "Bimagrumab" is derived from the Latin words 'bi' meaning two, 'magrus' meaning lean, and 'mab' is an abbreviation for monoclonal antibody. The name reflects the drug's function as a dual-action monoclonal antibody designed to treat muscle wasting conditions.
Mechanism of Action
Bimagrumab works by blocking the activin type II receptor and stimulating muscle growth by inhibiting myostatin, a protein that inhibits muscle differentiation and growth. This results in an increase in muscle mass and strength.
Clinical Trials
Bimagrumab has undergone several clinical trials for various conditions. In 2013, a phase II trial showed that the drug increased muscle mass and improved function in patients with sarcopenia. It is currently undergoing phase III trials for the treatment of inclusion body myositis.
Related Terms
- Monoclonal Antibody
- Sarcopenia
- Muscle Wasting
- Novartis
- Activin Type II Receptor
- Myostatin
- Clinical Trials
- Inclusion Body Myositis
External links
- Medical encyclopedia article on Bimagrumab
- Wikipedia's article - Bimagrumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski